Welcia stock holds as fiscal 2025 sales and profit remain the focus

Welcia Holdings Co., Ltd. (JP3155700002) remains in focus after its latest disclosed fiscal 2025 numbers, with investors still weighing sales, profit, and store growth against the current share valuation. The company reported revenue of JPY 1,195.3 billion in fiscal 2025, operating profit of JPY 42.7 billion, and 2,725 stores as of fiscal 2025.

Fiscal 2025 sales and profit

Welcia’s fiscal 2025 revenue of JPY 1,195.3 billion compared with JPY 1,115.5 billion in fiscal 2024, a gain of 7.2%. Operating profit rose to JPY 42.7 billion from JPY 39.8 billion a year earlier, while net income attributable to owners of the parent reached JPY 24.1 billion in fiscal 2025 versus JPY 22.6 billion in fiscal 2024. These figures show that the business entered the new year with firmer earnings momentum than in the prior period.

The store base also expanded to 2,725 locations in fiscal 2025 from 2,674 in fiscal 2024, adding 51 stores year over year. That matters because Welcia’s pharmacy and drugstore model depends on scale, local density, and repeat traffic, not only headline sales growth.

Store count up 51

For investors, the key question is whether the 7.2% revenue increase and the 7.3% rise in operating profit can keep pace with costs tied to labor, rent, and product mix. The combination of JPY 1,195.3 billion in sales and JPY 42.7 billion in operating profit implies an operating margin of 3.6% in fiscal 2025, up from 3.6% in fiscal 2024 by a small margin rather than a dramatic shift.

That margin profile is typical for a large Japanese drugstore chain and leaves less room for disappointment if promotional pressure or procurement costs move against the company. The fiscal 2025 comparison also shows that growth came from both the top line and the store network, not from a single one-off item.

Welcia pharmacy business

Welcia’s core retail engine is its pharmacy-led drugstore network, which supports recurring demand in prescription drugs, over-the-counter medicine, daily necessities, and health-related products. The company’s fiscal 2025 store count of 2,725 underlines why scale remains central to the investment case.

That base gives Welcia more reach for prescription dispensing and private-label merchandising, while also increasing the importance of same-store productivity. The 51-store increase in fiscal 2025 shows continued network expansion even in a mature domestic retail environment.

Shares and valuation

Welcia stock was last valued at JPY 1,850 as of 23 July 2026, giving the market a fresh reference point against fiscal 2025 revenue of JPY 1,195.3 billion and operating profit of JPY 42.7 billion. The share price needs to be read alongside those 2025 metrics because the stock is now tied to whether the company can sustain its earnings pace into the new year.